Weeks after allaying concerns from high-profile activist investor Carl Icahn with the hiring of former Stryker CEO Steve MacMillan, Hologic is facing demands from the same activist that prompted Charles River Laboratories to spike a $1.6 billion merger with WuXi PharmaTech in 2010. Hologic (NSDQ:HOLX) is facing another challenge from an activist investor, just weeks after putting ex-Stryker (NYSE:SYK) CEO Steve MacMillan into the corner office to allay the concerns of famed corporate raider Carl Icahn. Relational Investors and principals Ralph Whitworth and David Batchelder began buying up shares of Bedford, Mass.-based Hologic in August 2013, according to a regulatory filing, and now control some 20 million shares for a 7.3% stake in the women’s healthcare firm.
Help employers find you! Check out all the jobs and post your resume.
